143 related articles for article (PubMed ID: 27563805)
1. (99m)Tc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma.
Zhang Z; Zhao X; Ding C; Wang J; Zhang J; Wang F
Cancer Biother Radiopharm; 2016 Sep; 31(7):238-45. PubMed ID: 27563805
[TBL] [Abstract][Full Text] [Related]
2. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
3. Integrin Imaging with
Jin X; Liang N; Wang M; Meng Y; Jia B; Shi X; Li S; Luo J; Luo Y; Cui Q; Zheng K; Liu Z; Shi J; Li F; Wang F; Zhu Z
Radiology; 2016 Dec; 281(3):958-966. PubMed ID: 27479638
[TBL] [Abstract][Full Text] [Related]
4. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
[TBL] [Abstract][Full Text] [Related]
5. ⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.
Ji B; Chen B; Wang T; Song Y; Chen M; Ji T; Wang X; Gao S; Ma Q
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1362-70. PubMed ID: 25947573
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study.
Zhu Z; Miao W; Li Q; Dai H; Ma Q; Wang F; Yang A; Jia B; Jing X; Liu S; Shi J; Liu Z; Zhao Z; Wang F; Li F
J Nucl Med; 2012 May; 53(5):716-22. PubMed ID: 22499615
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
8. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
9. Advantages of
Lv N; Gao S; Bai L; Ji B; Xue J; Ge X; Chen B
Ann Nucl Med; 2019 Jan; 33(1):39-46. PubMed ID: 30218281
[TBL] [Abstract][Full Text] [Related]
10.
Xiao L; Yu S; Xu W; Sun Y; Xin J
Korean J Radiol; 2023 Nov; 24(11):1142-1150. PubMed ID: 37899523
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.
Chen G; Ouyang Z; Wang F; Wu H; Jia B; Chordia MD
Cancer Invest; 2017 Feb; 35(2):108-115. PubMed ID: 28135863
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of
Gao R; Zhang GJ; Wang YB; Liu Y; Wang F; Jia X; Liang YQ; Yang AM
Sci Rep; 2018 Jan; 8(1):473. PubMed ID: 29323252
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study.
Yan B; Fu T; Liu Y; Wei W; Dai H; Fang W; Wang F
Medicine (Baltimore); 2018 Oct; 97(40):e12441. PubMed ID: 30290601
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
15. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
16. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
17. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
19. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Hsu KH; Huang YH; Tseng JS; Chen KC; Ku WH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Lung Cancer; 2019 Jan; 127():37-43. PubMed ID: 30642549
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
